173 related articles for article (PubMed ID: 37391697)
1. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
Foldi J; Tsagianni A; Salganik M; Schnabel CA; Brufsky A; van Londen GJ; Pusztai L; Sanft T
BMC Cancer; 2023 Jun; 23(1):606. PubMed ID: 37391697
[TBL] [Abstract][Full Text] [Related]
2. The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience.
Shah S; Shaing C; Khatib J; Lodrigues W; Dreadin-Pulliam J; Anderson BB; Unni N; Farr D; Li HC; Sadeghi N; Syed S
Clin Breast Cancer; 2022 Dec; 22(8):823-827. PubMed ID: 36089460
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Sanft TB; Wong J; O'Neal B; Siuliukina N; Jankowitz RC; Pegram MD; Fox JR; Zhang Y; Treuner K; O'Shaughnessy JA
J Natl Compr Canc Netw; 2024 Mar; 22(2):99-107. PubMed ID: 38437792
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Mamounas EP; Bandos H; Rastogi P; Zhang Y; Treuner K; Lucas PC; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil S; Paik S; Swain SM; Sgroi DC; Schnabel CA; Wolmark N
Clin Cancer Res; 2024 May; 30(9):1984-1991. PubMed ID: 38376912
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine in extended adjuvant endocrine therapy for breast cancer.
Tesch ME
Curr Opin Oncol; 2023 Nov; 35(6):453-460. PubMed ID: 37621168
[TBL] [Abstract][Full Text] [Related]
10. Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer.
Anandan A; Sharifi M; O'Regan R
Curr Treat Options Oncol; 2020 Aug; 21(10):84. PubMed ID: 32803324
[TBL] [Abstract][Full Text] [Related]
11. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.
Zhang Y; Schnabel CA; Schroeder BE; Jerevall PL; Jankowitz RC; Fornander T; Stål O; Brufsky AM; Sgroi D; Erlander MG
Clin Cancer Res; 2013 Aug; 19(15):4196-205. PubMed ID: 23757354
[TBL] [Abstract][Full Text] [Related]
13. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
14. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Jankowitz RC; Cooper K; Erlander MG; Ma XJ; Kesty NC; Li H; Chivukula M; Brufsky A
Breast Cancer Res; 2011 Oct; 13(5):R98. PubMed ID: 21999244
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
Zhao F; Ren D; Shen G; Ahmad R; Dong L; Du F; Zhao J
Crit Rev Oncol Hematol; 2020 Dec; 156():103114. PubMed ID: 33045493
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
[TBL] [Abstract][Full Text] [Related]
17. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
Jerevall PL; Brock J; Palazzo J; Wieczorek T; Misialek M; Guidi AJ; Wu Y; Erlander MG; Zhang Y; Schnabel CA; Goss PE; Horick N; Sgroi DC
Breast Cancer Res Treat; 2019 Jan; 173(2):375-383. PubMed ID: 30350269
[TBL] [Abstract][Full Text] [Related]
18. Impact of non-adherence to endocrine therapy on recurrence risk in older women with stage I breast cancer after breast-conserving surgery.
Rodin D; Sutradhar R; Jerzak KJ; Hahn E; Nguyen L; Castelo M; Fatiregun O; Fong C; Mata DGMM; Trebinjac S; Paszat L; Rakovitch E
Breast Cancer Res Treat; 2023 Aug; 201(1):77-87. PubMed ID: 37326765
[TBL] [Abstract][Full Text] [Related]
19. Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests.
Saponaro M; Annunziata L; Turla A; Viganò I; De Laurentiis M; Giuliano M; Del Mastro L; Montemurro F; Puglisi F; De Angelis C; Buono G; Schettini F; Arpino G
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362392
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
